{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"123"}],"units":"Participants"}],"description":"Number of participants with any grade of drug-related serious adverse events (SAEs) in Neoadjuvant cohort","groups":[{"description":"Nivolumab administered intravenously (IV) over 30 minutes at 240 mg for 2 doses, on Day 1 and Day 15","id":"OG000","title":"Neoadjuvant"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All treated participants in the neoadjuvant cohort","reportingStatus":"POSTED","timeFrame":"From first dose to 30 days post last dose (Up to 2 months)","title":"Neoadjuvant: Number of Participants With Drug-Related Serious Adverse Events (SAEs)","type":"PRIMARY","unitOfMeasure":"Participants"}